Stock ALDX ALDEYRA THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Insiders Aldeyra Therapeutics, Inc.

Equities

ALDX

US01438T1060

Real-time Estimate Cboe BZX
Other stock markets
 03:18:27 2024-05-10 pm EDT 		5-day change 1st Jan Change
3.765 USD -4.44% Intraday chart for Aldeyra Therapeutics, Inc. -10.22% +6.41%
May. 08 Aldeyra Therapeutics Enrolls First Patient in Phase 3 Dry Eye Chamber Study MT
May. 08 Aldeyra Therapeutics, Inc. Enrolls First Patient in Phase 3 Clinical Trial Designed to Enable Potential Resubmission of New Drug Application of Reproxalap in Dry Eye Disease CI

Insiders

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Aldeyra Therapeutics Insider Sold Shares Worth $580,760, According to a Recent SEC Filing
MT
Omega Therapeutics Hires Aldeyra Therapeutics Chief Financial Officer Joshua Reed for Same Role
MT
Aldeyra Therapeutics, Inc. Announces Management Changes, Effective May 10, 2022
CI
Insider Trends: Insider Buying Continued with Purchase of Aldeyra Therapeutics Stock
MT
Aldeyra Therapeutics, Inc. Announces Retirement of Jesse I. Treu from the Board of Directors
CI
Insider Trends: Insider Purchase of Aldeyra Therapeutics Stock Extends 90-Day Positive Trend
MT
Insider Trends: Insider Purchase Eases Back 90-Day Trend of Sales at Aldeyra Therapeutics
MT
Aldeyra Therapeutics, Inc. Announces Executive Changes
CI
Aldeyra Therapeutics, Inc. Appoints Paul Karpecki to Anterior Segment Scientific Advisory Board
CI
Aldeyra Therapeutics, Inc. Appoints Nancy Miller-Rich to Board of Directors
CI
Aldeyra Therapeutics Announces Promotion of Stephen G. Machatha, Ph.D. to Position of Senior Vice President of Technical Operations
CI
Aldeyra Therapeutics, Inc. Announces Promotion of David McMullin to Position of Chief Commercial Officer
CI
Aldeyra Therapeutics, Inc. Appoints David McMullin as Senior Vice President, Corporate Development and Strategy
CI
Aldeyra Therapeutics Appoints Richard H. Douglas to its Board of Directors
CI
Scott L. Young Steps Down from His Position as Chief Operating Officer of Aldeyra
CI
Aldeyra Therapeutics Appoints Mary Taylor, MPH as Senior Vice President, Regulatory Affairs
CI
Aldeyra Therapeutics, Inc. Appoints David J. Clark as Chief Medical Officer
CI
Aldeyra Therapeutics Expands Drug Development Team in Advance of NS2 Clinical Trials
CI
Aldeyra Therapeutics, Inc. Appoints Stephen Tulipano Chief Financial Officer, Effective from June 23, 2014
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ALDX Stock
  4. News Aldeyra Therapeutics, Inc.
  5. Insiders
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW